Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company built around complement inhibition, with pegcetacoplan as its core molecule. The company markets SYFOVRE for geographic atrophy secondary to age-related macular degeneration and EMPAVELI for paroxysmal nocturnal hemoglobinuria, with newer approvals expanding EMPAVELI into rare kidney diseases. Its business combines U.S. product commercialization with selective ex-U.S. partnering, most notably through Sobi for Aspaveli outside the United States. Apellis also continues to invest in pipeline programs that extend its complement biology platform into additional high-unmet-need diseases.

5,7 %

2,2 %

+28,5 %

3.14

2.70

— Apellis Pharmaceuticals, Inc.
%
Commercial ophthalmology44% Intravitreal pegcetacoplan sold as SYFOVRE for geographic atrophy secondary to AMD.
Commercial rare disease hematology/nephrology13% Systemic pegcetacoplan sold as EMPAVELI for PNH and newly approved kidney indications.
Licensing and collaboration revenue7% Product supply and royalty revenue from the Sobi collaboration outside the U.S.
Pipeline development36% Preclinical and clinical programs extending complement inhibition into new diseases.

Apellis sells primarily to U.S. specialty physicians and the patients they treat, rather than to broad retail consumers...

  • Retina specialists and GA patientsprimary

    They use SYFOVRE to slow progression in geographic atrophy, a chronic ophthalmology market with concentrated prescribers and reimbursement sensitivity.

  • Hematology patients with PNHprimary

    They buy EMPAVELI through treating physicians to control complement-driven hemolysis in a rare disease setting.

  • Nephrology patients with C3G and IC-MPGNsecondary

    They use EMPAVELI for newly approved kidney indications where specialist diagnosis and access pathways are critical.

  • Specialty pharmacies and distributorsprimary

    They purchase and distribute product within the U.S. specialty channel and are important to inventory flow, returns and rebates.

  • Sobi collaboration partnersecondary

    Sobi buys product and commercializes Aspaveli outside the U.S., generating supply and royalty revenue for Apellis.

Apellis is operationally centered in the United States, where it recognizes product revenue from EMPAVELI and SYFOVRE...

  • •United States is the core commercial market for both marketed products
  • •U.S. sales drive product revenue for SYFOVRE and EMPAVELI
  • •Europe matters through Sobi's Aspaveli commercialization and royalties
  • •Ex-U.S. access depends on partner execution and local approvals
  • •Commercial infrastructure is built primarily for the U.S. specialty channel

Apellis is focused on maximizing the commercial opportunity for its two marketed pegcetacoplan products while...

01
Grow SYFOVRE commercial uptakeshort-term

SYFOVRE is the largest commercial opportunity and requires continued market education and reimbursement execution in a concentrated retina market.

02
Expand EMPAVELI into additional indicationsmedium-term

New approvals in C3G and IC-MPGN broaden the addressable rare disease market and diversify revenue beyond PNH.

03
Advance pipeline beyond pegcetacoplanlong-term

A broader pipeline reduces concentration risk and supports long-term growth if current products mature or face competition.

Apellis remains exposed to the commercial risk of relying on a small number of products, especially SYFOVRE and...

high

Dependence on a small number of products

Most revenue is tied to SYFOVRE and EMPAVELI, so any safety issue, slower uptake or label setback would materially affect results.

Scope
SYFOVRE and EMPAVELI
Materiality
high
high

Competitive pressure in rare disease markets

EMPAVELI faces competition from oral and other therapies, which can reduce demand and pricing power.

Scope
PNH and future EMPAVELI indications
Materiality
high
high

Third-party manufacturing and supply disruption

The company relies on a small number of contract manufacturers for active ingredient and finished product supply.

Scope
Commercial and clinical supply
Materiality
high
medium

Reimbursement and rebate pressure

Specialty drugs require payor access and can see higher rebates, returns and channel deductions that reduce net revenue.

Scope
U.S. specialty pharmacy channel
Materiality
high
medium

Pipeline and regulatory failure

Future growth depends on approvals and clinical success in new indications and programs, which are inherently uncertain.

Scope
Development pipeline
Materiality
high
Revenue recognition and variable consideration
Can shift revenue between periods if estimates change
Specialty channel reserves
Affects net sales and gross-to-net deductions
Collaboration revenue from Sobi
Creates timing variability in licensing and other revenue
Inventory and accrued R&D estimates
Can affect cost of sales, operating expenses and working capital

ALUMIS INC.

ALMS · Pharmaceutical Preparations

Amylyx Pharmaceuticals, Inc.

AMLX · Pharmaceutical Preparations

EXELIXIS, INC.

EXEL · Biological Products, (No Diagnostic Substances)

Apogee Therapeutics, Inc.

APGE · Biological Products, (No Diagnostic Substances)

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

Axsome Therapeutics, Inc.

AXSM · Pharmaceutical Preparations

: 11/08/2026